3rd Non-Viral RNA Delivery Systems Summit

There has been many exciting investments, collaborations and advancements in the field, for instance Capricor Therapeutics and the National Institutes of Health collaborate on a clinical trial for a novel exosome-based vaccine. However, delivery remains the biggest challenge so far for the RNA field, to get drugs to the right cell type with specificity, tolerability and effective targeting.

Hence, this October the 3rd Non-Viral RNA Delivery Systems Summit is being brought back to Boston as the first and only industry-led event focussed on non-viral delivery systems, such as LNPs, exosomes, polymers, peptides and more, for RNA payloads to advance potent and efficacious therapeutics towards the patients in need.

Join 80+ RNA delivery experts from the likes of AstraZeneca, Sanofi, Novo Nordisk, Tessera Therapeutics, Replicate Biosciences, Sanegene Bio and more to discuss novel and innovative delivery strategies for overcoming the challenges of endosomal escape and delivering beyond the liver to advance RNA therapeutics into the clinic and towards approval.

URLs:
Website: https://go.evvnt.com/2422307-0?pid=176 
Tickets: https://go.evvnt.com/2422307-2?pid=176 
Brochure: https://go.evvnt.com/2422307-3?pid=176 

Time: 9:00 AM - 5:00 PM

Prices:
Conference + 2 Workshops - Drug Developer Pricing: USD 4197.00,
Conference + 1 Workshop - Drug Developer Pricing: USD 3598.00,
Conference Only - Drug Developer Pricing: USD 2999.00,
Conference + 2 Workshops - Academic Pricing: USD 3597.00,
Conference + 1 Workshop - Academic Pricing: USD 3098.00,
Conference Only - Academic Pricing: USD 2599.00,
Conference + 2 Workshops - Service Provider Pricing: USD 5097.00,
Conference + 1 Workshop - Service Provider Pricing: USD 4398.00,
Conference Only - Service Provider Pricing: USD 3699.00

Speakers: Andrew Geall, Co-Founder and Chief Development Officer, Replicate Bioscience, Anna Perdrix, Founder and Co-Chief Executive Officer, Sixfold Bioscience, Arun Raturi, Chief Scientific Officer, Entos Pharmaceuticals, Chad Miller, Head of Research, Nosis Biosciences, Clayton Deighan, Sales and Applications Manager, Nano FCM, Eric Dane, Associate Principal Scientist, AstraZeneca Pharmaceuticals, Research and Development, Gilles Divita, Chief Executive Officer, Divincell, Han Gu, Scientist II, Tessera Therapeutics, Jessica Rouge, Associate Professor, University of Connecticut, Kanika Suri, Drug Product and Device Development, Chemistry, Manufacturing and Controls Scientist, Kanika Suri, Laura Rotolo, Formulation Chemist, Emory University, Luis Brito, Vice President, Delivery Platform, Beam Therapeutics, Mansoor Amiji, University Distinguished Professor, Northeastern University, Minghao Sun, Vice President, Head of Research and Product Development, Capricor Therapeutics, Miriam Bujny, Chief Development Officer, Sapreme Technologies, Poulami Talukder, Principal Scientist, Tiba Biotech, Qi-Ying Hu. Chief Executive Officer, Corti Therapeutics, Russell Johnson, Vice President - Formulation and Delivery, Omega Therapeutics, Saswata Karmakar, Director, Chemistry, Sanofi, Silvia Piccinotti, Associate Director, ARMMs Engineering, Vesigen Therapeutics, Umberto Capasso Palmiero, Senior Scientist, Novo Nordisk, Weimin Wang, Chief Executive Officer, SanegeneBio, Zi Jun Emma Wang, Chief Technology Officer, YolTech Therapeutics